Search Within

Solid Tumor Oncology Division

Formats
  1. Journal Article (10875)
  2. Meeting Abstract (9493)
  3. Review (551)
  4. Book Section (417)
  5. Editorial (334)
  6. Guidelines (157)
  7. Correspondence (116)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (54)
  11. Book Whole (27)
Groups
  1. Department of Medicine (22168)
  2. GSK Faculty (5911)
  3. Genitourinary Oncology Service (5637)
  4. Survivorship Research (5217)
  5. Gastrointestinal Oncology Service (4673)
  6. Breast Medicine Service (4144)

More Groups

People
  1. Robert Motzer (1247)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (870)
  6. Leonard Saltz (791)

More People

Years
  1. 2025 (569)
  2. 2024 (1386)
  3. 2023 (1381)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1536)

More Years

Publications
  1. Journal of Clinical Oncology (5282)
  2. Annals of Oncology (1295)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (772)
  5. Journal of Thoracic Oncology (531)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5573)
  2. Elsevier Inc. (2654)
  3. American Association for Cancer Research (2322)
  4. Oxford University Press (1812)
  5. Nature Publishing Group (1030)
  6. Springer (979)

More Publishers

Results (22190)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Survival and patterns of failure in oligometastatic esophagogastric cancer
    Meeting Abstract

    Yariv, O.; Hilal, L.; Ku, G. Y.; Molena, D.; Janjigian, Y. Y.; Ilson, D. H.; Maron, S.; Sihag, S.; Strong, V. E.; Crane, C. H.; more...
    Radiotherapy and Oncology (2025)

    Fulltext@MSK | Save
  • Nivolumab plus relatlimab vs nivolumab alone for the adjuvant treatment of completely resected stage III-IV melanoma: Primary results from RELATIVITY-098
    Meeting Abstract

    Long, G. V.; Ascierto, P. A.; Guo, J.; Chandra, S.; Tarhini, A. A.; Couselo, E. M.; Del Vecchio, M.; De Melo, A. C.; Gogas, H.; Dummer, R.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): Primary analysis of Ph3 DeLLphi-304
    Meeting Abstract

    Rudin, C. M.; Mountzios, G. S.; Sun, L.; Cho, B. C.; Demirci, U.; Baka, S.; Gumus, M.; Lugini, A.; Ciuleanu, T. E.; Ahn, M. J.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes
    Meeting Abstract

    Attard, G.; Agarwal, N.; Graff, J. N.; Sandhu, S.; Efstathiou, E.; Özgüroğlu, M.; de Santana Gomes, A. J. P.; Vianna, K. C. M.; Luo, H.; Cheng, H. H.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Association between empirical dietary inflammatory pattern (EDIP) and survival in patients with stage III colon cancer: Findings from CALGB/SWOG 80702 (Alliance)
    Meeting Abstract

    Char, S. K.; Shi, Q.; Zemla, T.; Ma, C.; Cheng, E.; Kumthekar, P.; Guthrie, K. A.; Couture, F.; Kuebler, J. P.; Kumar, P.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (BREAKWATER): Progression-free survival and updated overall survival analyses
    Meeting Abstract

    Elez, E.; Yoshino, T.; Shen, L.; Lonardi, S.; Van Cutsem, E.; Eng, C.; Kim, T. W.; Wasan, H. S.; Desai, J.; Ciardiello, F.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • NAPOLI 3, a phase 3 study of NALIRIFOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Final overall survival (OS) analysis and characteristics of the long-term survivors
    Meeting Abstract

    Chung, V.; Kochenderfer, M. D.; Natarajan, N.; Williams, G. R.; Laursen, A. A.; Cockrum, P.; Rhodes, W.; Surinach, A.; Zhang, L.; Li, J.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • FORTE: A phase 2 master protocol assessing plixorafenib for BRAF-altered cancers
    Meeting Abstract

    Schreck, K. C.; De La Fuente, M. I.; Rine, J.; Kline, I.; Shephard, S. P.; Ahnert, J. R.; Sherman, E. J.; Yaeger, R.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC)
    Meeting Abstract

    Sinicrope, F. A.; Ou, F. S.; Arnold, D.; Peters, W.; Behrens, R. J.; Lieu, C. H.; Matin, K.; Cohen, D. J.; Potter, S. L.; Frankel, W. L.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study
    Meeting Abstract

    Hamilton, E. P.; De Laurentiis, M.; Jhaveri, K. L.; Hu, X.; Ladoire, S.; Patsouris, A.; Zamagni, C.; Cui, J.; Cazzaniga, M.; Cil, T.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save